HOW TO INVEST IN CANCER

Contact Nextech Invest

How To Invest In Cancer

NEXTECH INVEST – The first private equity fund advisor investing exclusively in oncology companies

In this episode, veteran road warrior Scott Arnell takes you out on the road to Nextech Invest biotech investors in Zurich to meet Alfred Scheidegger and his team of experienced biopharma executives who have a double-digit IRR track record in the Nextech II oncology fund, the world’s first private equity healthcare investment fund focused solely on investing equity in late-stage biotech cancer treatment development companies that are acquired by major pharmaceutical companies.

In this segment, Alfred explains how to successfully invest in cancer with an investment strategy that targets the underlying pharma market structure: 1) huge and growing (ageing) cancer therapeutics market demand, 2) inelastic price sensitivity for innovative cancer treatments, and 3) exit via trade sales to major pharma who must acquire R&D companies to fill their drug pipeline regardless of economic downturns or market volatility.   They invest in companies with management that has proven success in cancer drug development and patented technologies that are structured for acquisition by a major pharmaceutical company within three years.

Nextech Invest’s competitive advantage is their scientific advisory board comprised of six world renown oncology experts in cancer science, drug development and market intelligence who have an intimate knowledge of the competitive landscape in oncology, clinical-stage companies and cancer products.  They are all exclusive to Nextech Invest in private equity investment advising and provide a unique assessment of the commercial potential of oncology products, cancer treatments and companies developing oncology therapies.

The Nextech III biotech investment fund builds on the Nextech II oncology focused investment platform and was launched in April 2010.  To achieve investor transparency, the Nextech III oncology private equity fund is an onshore, closed-end Swiss Limited Partnership registered in Switzerland with FINMA.

Meet the rest of the team and find out why Alfred take 50 kicks to the stomach in Japan in our follow-on segment “Who is Alfred Scheidegger?”

Contact Nextech Invest

THE CANCER INVESTORS

Contact Nextech Invest

THE CANCER INVESTORS

WHO IS DR. ALFRED SCHEIDEGGER? Meet the Nextech Invest Private Equity Investment Team

Meet the only Swiss investment fund manager with a black belt achieved at an exclusive karate club in Japan! Find out how he did it and meet the rest of the Nextech Oncology private equity fund investment  team.   This bonus segment post picks up from where the previous Nextech Invest overview episode, “HOW TO INVEST IN CANCER” left off.  Scott Arnell takes you behind the scenes at the Nextech Invest headquarters in Zurich to delve into the backgrounds of CEO Alfred Scheidegger and his team of experienced biotech private equity investors who launched the world’s first private equity healthcare investment fund focused solely on late-stage biotech R&D cancer treatment company investments achieving exits through trade sales to major pharma within three years.

In this segment, you will meet Alfred Scheidegger on a more personal level as he describes his formative education, doctoral studies in Japan, why he speaks fluent Japanese and his early days in the pharmaceutical industry in Basel, Switzerland that put him on the path to launching Nextech Invest in 1998 from which he launched three healthcare biotech investment funds.  You will also get an impromptu tour of the Nextech Invest headquarters office and meet the key members of the investment team: Myoung-Ok Kwon, Managing Partner; Rudolf Gygax, Managing Partner; Mátyás Végh, Managing Partner; Roland Ruckstuhl, Chief Financial Officer; and Camille Therre, Associate.

You will be able to get a good feel for team Alfred has assembled, their extensive vertical experience in the cancer product and oncology drug development investment space and ability to achieve investment exits via trade sales to major pharmaceutical companies.  You will also find out first hand why Alfred took 50 kicks to the stomach in Japan and if you hang on long enough, you’ll see Scott Arnell taken down by Camille Therre’s martial arts expertise.

Contact Nextech Invest